Skip to main content

Table 2 Itemized cost results

From: Cost effectiveness of intermittent screening followed by treatment versus intermittent preventive treatment during pregnancy in West Africa: analysis and modelling of results from a non-inferiority trial

Type of cost Cost parameter Cost in US$ 2012, mean (95 % CI)
Intervention cost Average SP price per administrationa 0.2 (0.16–0.25)
Average AL price per administrationa 2.39 (1.71–3.06)
Average RDT price per administrationa 0.81 (0.58–0.90)
HCW time cost per dose of IPTp-SP 0.59 (0.33–0.91)
HCW time cost per administration of ISTp-AL if screened negative 0.64 (0.36–1.00)
HCW time cost per administration of ISTp-AL if screened positive 0.84 (0.47–1.31)
Total cost per administration of IPTp-SP (HCW time and commodity cost) 0.79 (0.53–1.12)
Total cost per administration of ISTp-AL if screened negative (HCW time and commodity cost) 1.45 (1.12–1.85)
Total cost per administration of ISTp-AL if screened positive (HCW time and commodity cost) 4.06 (3.29–4.97)
Health provider costs excluding medical supplies Cost per OP visit 11.78 (9.18–14.68)
Cost per IP day adult 35.27 (19.99–55.07)
Cost per paediatric IP day (nursery) 63.51 (36.3–99.27)
Health provider costs of consequences Total average short term cost per LBW baby 40.93 (19.52–71.19)
Total average cost per moderate/severe anaemia case 10.15 (6.76–15.17)
Total average cost per clinical malaria case 13.71 (6.12–24.65)
  1. AL arthemether-lumefantrine; HCW health care worker; IP inpatient; IPTp-SP intermittent preventive treatment with sulfadoxine-pyrimethamine; ISTp-AL intermittent screening and if positive followed by treatment with artemether-lumefantrine; LBW low birth weight; OP outpatient; SP sulfadoxine-pyrimethamine
  2. aIncluding freight, insurance, wastage and in country transport